AGM Presentation

Resonance Health has seen significant revenue growth and diversification since FY23, with a strong revenue growth of approximately 45% CAGR. The company has expanded its addressable global market, focusing on new imaging endpoints for metabolic and obesity, alongside a growth strategy that aims to increase share of wallet through more therapeutic areas, services, and customers. Growth opportunities include expanding into new therapeutic areas and earlier stage trials, as well as acquisitions in the US and Europe.

The company's FY26 guidance remains at a revenue of $17M and underlying Operating EBITDA of $2M, with plans to grow underlying EBITDA margins to ~12% and target margins of ~25% in the future. Resonance Health prides itself on its deep expertise in liver and related metabolic areas and serves global pharma clients with standardized trial protocols. Investors are encouraged to inquire for further details and clarification on the company's expansion plans and growth opportunities.